TEC: Evidence Based Therapeutics
Therapeutics Education Collaboration
Medication Mythbusters – Home of the Best Science (BS) Medicine Podcast

Episode 214: PREMIUM – two more diabetes treatments that fail us yet again

In episode 214, James and Mike notch the discussion up to a PREMIUM level yet again. We discuss the 2 new gliptin studies, SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) and we find that low and behold these medications lower glucose and have no impact on cardiovascular disease. At the end we lament this lack of cardiovascular benefit by singing a chorus of “Another One Bites The Dust”.

Show notes

1) SAVOR-TIMI 53 – saxagliptin and cardiovascular outcomes

September 2, 2013DOI: 10.1056/NEJMoa1307684 

2) EXAMINE – alogliptin and cardiovascular outcomes

September 2, 2013DOI: 10.1056/NEJMoa1305889

Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!


Upcoming Events

Practical Evidence for Informed Practice (PEIP) – October 22-23, 2021

This will be a live-streamed course from Edmonton, AB. Registration Opens August 2021

BS Medicine Podcast

BedMed: The High Blood Pressure Study

This pragmatic trial is now recruiting in BC. Make a difference and get involved with pragmatic trials (www.pragmatictrials.ca)

PEER Tools